MIND MEDICINE MINDMED INC. [MMEDF: OTCQB]

1.89 0.25 (15.24%) 12/04/2020 Delayed 15 minutes

Open	$1.70	Daily Range	$1.66-$1.92
Prev. Close	$1.64	52 Week Range	$0.0833-$1.98
Volume	5,454,272

Quote Data Realtime

Inside Quote
Bid	Ask	Last Inside Change
$1.88 x 2500 shares	$1.89 x 1000 shares	12/05 7:44 AM EST

Level II Quote Montage

BID

ASK

MMID	Bid Price	Bid Size	Date/Time
ETRF	1.88	1300	12/04
CSTI	1.88	1000	12/04
NITE	1.88	200	12/04
CDEL	1.87	5005	12/04
INTL	1.87	800	12/04
JANE	1.86	5000	12/04
GTSM	1.85	6000	12/04
OTCX	1.84	700	12/04
GARC	1.71	3150	12/04
MAXM	1.38	100	12/03
LAFC	0.6572	1000	10/28
MCAP	0.54	1000	12/04
PUMA	0.0001	10000	12/04
BGCE	U		11/25
VALX	U		12/04

MMID	Ask Price	Ask Size	Date/Time
CSTI	1.89	1000	12/04
OTCX	1.90	3000	12/04
INTL	1.90	1505	12/04
JANE	1.91	5000	12/04
NITE	1.91	1000	12/04
ETRF	1.91	100	12/04
CDEL	1.92	1315	12/04
GTSM	1.92	100	12/04
MAXM	2.29	100	12/01
PUMA	2.58	100	12/04
LAFC	3.02	100	11/20
MCAP	3.07	100	12/04
BGCE	U		11/25
GARC	U		12/04
VALX	U		12/04

The quotes displayed here are published by market makers on the OTC Markets Group Inc. electronic inter-dealer quotation and trading system for OTC securities. Please see Terms of Service and Risk Warning for more information.

MMID - Market maker quotation published in OTC Link that meets the Inside market | MMID - Market maker quotation published in OTC Link | cMMID - Closed quote | Unpriced - Unpriced quote in OTC Link | MMIDu - Unsolicited market maker quotation published in OTC Link

Breakthrough Mental Healing

We help patients unlock the healing power of the mind through Psychedelic Inspired Medicines & Experiential Therapies.

Together we can overcome.

11/25/20

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

We're Creating a New Toolset for Mental Health & Addiction

Solving for mental illness and addiction requires a novel approach

ANXIETY

Experiential Therapies

Transcending traditional mental healthcare to treat Anxiety

ADHD & ADDICTION

Psychedelic Inspired Medicines

Unlocking a new kind of healing for ADHD & Addiction

Psychedelic Innovation

Next-Gen R&D

Developing new compounds, therapies, methods and technologies to optimize patient outcomes

Advancing Psychedelic Inspired Medicines & Experiential Therapies Through Clinical Trials

We’re a New Kind of Pharma Company

Patients and therapists deserve care that transcends traditional symptom management cycles, advancing long-term mental healing.

View our approach

Our Healing Goes Beyond Just A Pill

01

Discover

Rigorous science of novel psychedelic compounds, therapies, and healing technologies in collaboration with leading institutions and researchers to make faster discoveries, together

02

Develop

Conducting clinical trials of psychedelic inspired medicines and experiential therapies within existing regulatory pathways to ensure the most effective & transformative healing experience possible

03

Deploy

We hold ourselves and our products to the highest levels of safety, efficacy, and accessibility so psychedelic inspired medicines and experiential therapies can one day reach patients in need

Partnerships

Groundbreaking R&D In the Birthplace of LSD: Basel, Switzerland

Partnerships

Training a New Generation of Psychiatrists at NYU

Partnerships

Studying the Science of Microdosing with Experts at Maastricht University

Press Release

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

Press Release

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Press Release

MindMed Upsizes Previously Announced Bought Deal Public Offering

Press Release

MindMed Announces $25 Million Bought Deal Public Offering

Press Release

MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities

More News

IN THE PRESS

This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?”

Shark Tank's Kevin O' Leary MindMed Investor

MindMed named one of 36 startups that could change the world

MindMed could have the key to providing the upsides of psychedelic drugs for both focus and addiction treatment—while cutting out the downsides of tripping.”

Meet the Team

Our interdisciplinary team of drug development veterans, savvy technologists, and mental health experts was purpose-built to tackle these challenges. With over a century of combined experience in product development and commercialization, we have the know-how and the heart to introduce a better approach to mental health.

MEET MINDMED